Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions
about
Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsFusarium infections in immunocompromised patientsInvasive mold infections in solid organ transplant recipientsFusarium infection: report of 26 cases and review of 97 cases from the literaturePosaconazole: an oral triazole with an extended spectrum of activityTrypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental ModelResolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case reportPosaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.Skin Microvascular Thrombosis in Fusarium Infection in Two Early Biopsied Cases.Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantationIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settingsClinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis.Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.The challenge of managing fusariosisCross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay.Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year ExperienceRole of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience.Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in CanadaSingle-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections.International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.Role of posaconazole in the management of oropharyngeal and esophageal candidiasisNosocomial fungal infections: epidemiology, diagnosis, and treatment.Posaconazole: a new broad-spectrum antifungal agent.Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogrPosaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Posaconazole treatment in Korea: single-center experience over 5 years.Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Current options in antifungal pharmacotherapy.Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteersInvasive fungal infections in patients with cancer in the Intensive Care Unit.
P2860
Q24603297-6186959E-059F-41F9-A7C8-A7D8D8A83079Q24685627-F4DB178E-20BB-4A51-8F97-7C4F537F7DF0Q26823811-344C97F4-4604-4F65-95EB-A51D3271C2F1Q27014001-49F03568-3873-4DBE-96F7-E0B9B6FC64EBQ28291282-5C17B1C4-3E87-436E-9037-EC2688808C30Q28553573-7D8BBA48-0A77-475E-9E8A-5979D217D4D2Q33284273-C67EDF8B-57C1-44EF-A1FB-B3974DBF45B1Q33798286-4585AE0D-8D8E-4988-97BE-9304B68D4223Q33798313-E6FFDF3C-93C6-4C1E-9334-38473A32E311Q34151084-3048C565-DC55-4963-BE9A-502CAC7A8BD9Q34336048-4DC0B964-A402-4A4D-BCAA-1F4A3643CC97Q34452574-98EBF1CC-4490-4472-8880-5D8520C6857EQ34680661-7C51337D-5D9A-4E2C-B3D7-2A8AFEA0662BQ34764156-A5F61DFE-EAEE-4F0C-80C5-6C89D216D835Q35026481-B3527E58-9A51-4E2A-B7A8-4EB37B5EEC93Q35066891-A1FC143F-D286-46EF-B3E2-0DE68EE3086EQ35105840-4F665974-7B20-450C-A7F5-B55D2784E67BQ35533576-5CBC6E15-F541-4817-8D80-444A227DADC5Q35607672-333B8F50-38E0-4A8F-92EF-CC48E55F9275Q35693680-BE6FF2D2-10F2-4BC6-B62C-79CA36759314Q35806844-DD983D87-5BA3-432F-9D4D-21CC3E0F40A1Q35916585-5D06BAD3-6712-4B32-B2B1-E6D442444DC3Q36068691-A9B769A6-DFEF-4091-9CA5-6B6F1907896DQ36111766-A16EBC50-872A-48BC-8466-35F999796479Q36171677-93BF1A19-2DFD-4FD0-9053-5E98327E3952Q36308059-B6786486-AA5D-41C7-9B79-0CA7A2360CE2Q36568458-562574C1-C04F-418F-8653-9C8EA660599BQ36571990-20710EC3-0499-4D31-A733-C3A5791B6680Q36642964-75F13623-9C24-4729-883A-844B6ECFE7C5Q36825717-12FCC1CF-68A3-4437-8938-41356B8D3390Q36828159-4F7BF937-F3A0-4DCB-A711-9026BEACD238Q37036246-1E7AB5DB-6E5E-40B2-B9C0-24CF3C750DAAQ37052755-4AB8FB7D-7EBC-4937-9493-707D2D40087AQ37055215-9BED550A-92E9-49DD-B756-5DE095F96F07Q37094649-F9AF67F0-B802-4C9F-B533-1E38A0AE3684Q37114436-C1025AD3-0042-4736-BB68-E8C48335F76BQ37115829-2CBEB7D4-43C2-4CD1-9FB3-1A94B95440D2Q37151326-61824661-A60A-46CE-91B8-9C0EB6E8159BQ37247780-A1601D2C-D779-4E47-88B9-D99F1C50B8F4Q37373771-63F7BA98-DF6E-479D-B5A1-093E114423B6
P2860
Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@ast
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@en
type
label
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@ast
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@en
prefLabel
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@ast
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@en
P2093
P2860
P356
P1476
Posaconazole as Salvage Treatm ...... alignancy and Other Conditions
@en
P2093
D. P. Kontoyiannis
G. Corcoran
I. I. Raad
J. R. Graybill
R. Y. Hachem
P2860
P304
P356
10.1086/503425
P407
P577
2006-05-15T00:00:00Z